Published in Dialogues Clin Neurosci on January 01, 2005
Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell (1998) 12.66
The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell (1999) 7.99
Hypocretin (orexin) deficiency in human narcolepsy. Lancet (2000) 7.92
A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med (2000) 7.05
Reduced number of hypocretin neurons in human narcolepsy. Neuron (2000) 6.94
Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev (1999) 6.26
Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol (2001) 4.88
Behavioral correlates of activity in identified hypocretin/orexin neurons. Neuron (2005) 4.72
The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci (2001) 4.33
Insomnia and its treatment. Prevalence and correlates. Arch Gen Psychiatry (1985) 3.70
The neurobiology of sleep: genetics, cellular physiology and subcortical networks. Nat Rev Neurosci (2002) 3.13
Corticothalamic resonance, states of vigilance and mentation. Neuroscience (2000) 3.07
Chronic insomnia is associated with nyctohemeral activation of the hypothalamic-pituitary-adrenal axis: clinical implications. J Clin Endocrinol Metab (2001) 2.97
Dopaminergic role in stimulant-induced wakefulness. J Neurosci (2001) 2.91
Distribution of orexin receptor mRNA in the rat brain. FEBS Lett (1998) 2.90
Adenosine and sleep-wake regulation. Prog Neurobiol (2004) 2.84
Varying nicotine patch dose and type of smoking cessation counseling. JAMA (1995) 2.82
A new benzodiazepine pharmacology. J Pharmacol Exp Ther (2002) 2.75
Prevalence of sleep disorders in the Los Angeles metropolitan area. Am J Psychiatry (1979) 2.60
Heart rate variability in insomniacs and matched normal sleepers. Psychosom Med (1998) 2.49
Paradoxical timing of the circadian rhythm of sleep propensity serves to consolidate sleep and wakefulness in humans. Neurosci Lett (1994) 2.47
The physiology of brain histamine. Prog Neurobiol (2001) 2.45
The role of hypocretins (orexins) in sleep regulation and narcolepsy. Annu Rev Neurosci (2002) 2.28
Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci (2000) 2.16
Critical role of dorsomedial hypothalamic nucleus in a wide range of behavioral circadian rhythms. J Neurosci (2003) 2.15
Interaction between the corticotropin-releasing factor system and hypocretins (orexins): a novel circuit mediating stress response. J Neurosci (2004) 2.13
Anatomical, physiological, and pharmacological characteristics of histidine decarboxylase knock-out mice: evidence for the role of brain histamine in behavioral and sleep-wake control. J Neurosci (2002) 2.10
Arousal systems. Front Biosci (2003) 2.07
Effect of SCN lesions on sleep in squirrel monkeys: evidence for opponent processes in sleep-wake regulation. J Neurosci (1993) 2.04
Alcohol's effects on sleep in alcoholics. Alcohol Res Health (2001) 2.04
Sleep and depression--results from psychobiological studies: an overview. Biol Psychol (2001) 2.02
N-methyl-D-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability. Pharmacol Ther (2003) 1.99
Epidemiological study on insomnia in the general population. Sleep (1996) 1.90
Afferents to the ventrolateral preoptic nucleus. J Neurosci (2002) 1.86
Arousal: revisiting the reticular activating system. Science (1996) 1.59
Adenosine receptors in the nervous system: pathophysiological implications. Prog Neurobiol (2002) 1.59
GABA mechanisms and sleep. Neuroscience (2002) 1.56
Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci U S A (1996) 1.55
Daytime alertness in patients with chronic insomnia compared with asymptomatic control subjects. Sleep (1988) 1.49
Sleep effects of a 24-h versus a 16-h nicotine patch: a polysomnographic study during smoking cessation. Sleep Med (2006) 1.44
Diazepam-induced changes in sleep: role of the alpha 1 GABA(A) receptor subtype. Proc Natl Acad Sci U S A (2001) 1.39
Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist. J Pharmacol Exp Ther (1998) 1.38
Role of GABAA receptors in the regulation of sleep: initial sleep responses to peripherally administered modulators and agonists. Sleep (1999) 1.29
The effects of low doses of caffeine on human performance and mood. Psychopharmacology (Berl) (1987) 1.27
The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharmacol Sci (2004) 1.27
Brain structures and mechanisms involved in the control of cortical activation and wakefulness, with emphasis on the posterior hypothalamus and histaminergic neurons. Sleep Med Rev (2000) 1.26
A meta-analysis to assess the incidence of adverse effects associated with the transdermal nicotine patch. Drug Saf (1998) 1.21
Sleep-promoting effects of melatonin: at what dose, in whom, under what conditions, and by what mechanisms? Sleep (1997) 1.21
Cellular and behavioral neurobiology of alcohol: receptor-mediated neuronal processes. Clin Neurosci (1995) 1.20
Rapid tryptophan depletion, sleep electroencephalogram, and mood in men with remitted depression on serotonin reuptake inhibitors. Arch Gen Psychiatry (1998) 1.15
Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Res Online (1998) 1.14
Fos immunoreactivity in hypocretin-synthesizing and hypocretin-1 receptor-expressing neurons: effects of diurnal and nocturnal spontaneous waking, stress and hypocretin-1 administration. Neuroscience (2003) 1.14
Treatment of alcohol-dependent outpatients with acamprosate: a clinical review. J Clin Psychiatry (2001) 1.13
Variations in extracellular monoamines in the prefrontal cortex and medial hypothalamus after modafinil administration: a microdialysis study in rats. Neuroreport (2001) 1.11
Sleep research in affective illness: state of the art circa 1987. Sleep (1987) 1.11
Effects of adenosine on gabaergic synaptic inputs to identified ventrolateral preoptic neurons. Neuroscience (2003) 1.09
Comparative stimulant and diuretic actions of caffeine and theobromine in man. Clin Pharmacol Ther (1971) 1.05
Beta2-containing nicotinic receptors contribute to the organization of sleep and regulate putative micro-arousals in mice. J Neurosci (2004) 1.02
Convergence of circadian and sleep regulatory mechanisms on hypocretin-1. Neuroscience (2004) 1.01
Differential patterns of regional c-Fos induction in the rat brain by amphetamine and the novel wakefulness-promoting agent modafinil. Neurosci Lett (1998) 1.00
Role of catecholamines in the modafinil and amphetamine induced wakefulness, a comparative pharmacological study in the cat. Brain Res (1992) 0.99
Disinhibition of ventrolateral preoptic area sleep-active neurons by adenosine: a new mechanism for sleep promotion. Neuroscience (2004) 0.98
Tobacco withdrawal and nicotine replacement influence objective measures of sleep. J Consult Clin Psychol (1995) 0.98
Ionotropic glutamate receptors as sites of action for ethanol in the brain. Neurochem Int (1999) 0.97
Comparison of inhibition of monoamine uptake by cocaine, methylphenidate and amphetamine. Res Commun Chem Pathol Pharmacol (1978) 0.97
The sleep of patients with obsessive-compulsive disorder. Arch Gen Psychiatry (1982) 0.97
Wake-promoting actions of dopamine D1 and D2 receptor stimulation. J Pharmacol Exp Ther (2003) 0.97
Acute effects of transdermal nicotine on sleep architecture, snoring, and sleep-disordered breathing in nonsmokers. Am J Respir Crit Care Med (1994) 0.96
Orexin neurons of the hypothalamus express adenosine A1 receptors. Brain Res (2002) 0.95
Increased activation of anterior paralimbic and executive cortex from waking to rapid eye movement sleep in depression. Arch Gen Psychiatry (2004) 0.94
Selective stimulation of orexin receptor type 2 promotes wakefulness in freely behaving rats. Brain Res (2005) 0.94
Modulation of rhythmic brain activity by diazepam: GABA(A) receptor subtype and state specificity. Proc Natl Acad Sci U S A (2004) 0.94
The contribution of electrophysiology to knowledge of the acute and chronic effects of ethanol. Pharmacol Ther (1999) 0.93
Daytime alertness in patients with primary insomnia. Am J Psychiatry (1993) 0.92
Orexins: from neuropeptides to energy homeostasis and sleep/wake regulation. J Mol Med (Berl) (2002) 0.92
Novel uncompetitive N-methyl-D-aspartate (NMDA)-receptor antagonist MRZ 2/579 suppresses ethanol intake in long-term ethanol-experienced rats and generalizes to ethanol cue in drug discrimination procedure. J Pharmacol Exp Ther (2000) 0.91
Changes in sleep after acute and repeated administration of nicotine in the rat. Psychopharmacology (Berl) (1999) 0.91
Sleep microstructure around sleep onset differentiates major depressive insomnia from primary insomnia. J Sleep Res (2003) 0.91
Twenty-four-hour sleep-wake function and personality patterns in chronic insomniacs and healthy controls. Sleep (1987) 0.88
Dose-dependent effects of transdermal nicotine on early morning awakening and rapid eye movement sleep time in nonsmoking normal volunteers. J Clin Psychopharmacol (1994) 0.88
REM sleep and depression: common neurobiological control mechanisms. Am J Psychiatry (1982) 0.86
Depression in borderline patients: a prospective EEG sleep study. Psychiatry Res (1985) 0.86
Diazepam-induced changes on sleep and the EEG spectrum in mice: role of the alpha3-GABA(A) receptor subtype. Eur J Neurosci (2003) 0.86
The adenosine kinase inhibitor ABT-702 augments EEG slow waves in rats. Brain Res (2004) 0.86
Impact of experimentally induced serotonin deficiency by tryptophan depletion on sleep EEG in healthy subjects. Neuropsychopharmacology (1998) 0.85
Central effects of acamprosate: part 2. Acamprosate modifies the brain in-vivo proton magnetic resonance spectrum in healthy young male volunteers. Psychiatry Res (1998) 0.85
Pharmacodynamic effects of acamprosate on markers of cerebral function in alcohol-dependent subjects administered as pretreatment and during alcohol abstinence. Neuropsychobiology (2004) 0.85
The dopamine D1 receptor agonists, A68930 and SKF 38393, induce arousal and suppress REM sleep in the rat. Eur J Pharmacol (1993) 0.84
Evidence for alcohol anti-craving properties of memantine. Eur J Pharmacol (1996) 0.84
Predictors and timing of adverse experiences during trandsdermal nicotine therapy. Drug Saf (1999) 0.83
Sleep during acute dopamine D1 agonist SKF 38393 or D1 antagonist SCH 23390 administration in rats. Neuropsychopharmacology (1990) 0.82
Effect of modafinil and amphetamine on the rat catecholaminergic neuron activity. Neurosci Lett (1991) 0.82
A comparison of sleep EEGs in patients with primary major depression and major depression secondary to alcoholism. J Affect Disord (1993) 0.82
The relationship of sleep and anxiety in anxious subjects. Biol Psychol (1983) 0.82
Sleep and waking during acute histamine H3 agonist BP 2.94 or H3 antagonist carboperamide (MR 16155) administration in rats. Neuropsychopharmacology (1996) 0.82
Effects of a tryptophan-free amino acid drink challenge on normal human sleep electroencephalogram and mood. Biol Psychiatry (1998) 0.80
H3 receptor blockade by thioperamide enhances cognition in rats without inducing locomotor sensitization. Psychopharmacology (Berl) (2003) 0.80
The sleep of patients with panic disorder: a preliminary report. Psychiatry Res (1984) 0.80
Effects of abstinence from smoking on sleep and daytime sleepiness. Chest (1994) 0.79
Diagnostic and research applications of electroencephalographic sleep studies in depression. Conceptual and methodological issues. J Nerv Ment Dis (1990) 0.79